The Vicious Circle of Metabolic Dysfunction-Associated Steatotic Liver Disease When Micronutrient Deficiency Drives

Iulia Cristina Marginean1, Sergiu Marian Cazacu2, Mihaela Popescu3

  • 1Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Life (Basel, Switzerland)
|November 27, 2025
PubMed

Insights

Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to micronutrient deficiencies and gut dysbiosis. Addressing both is key to managing this growing liver disease burden.

Area of Science:

  • Hepatology and Gastroenterology
  • Nutritional Science
  • Microbiome Research

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, potentially progressing to severe liver conditions.
  • Dietary factors and micronutrient status are critical in MASLD development and progression.
  • The gut microbiome's role in MASLD is increasingly recognized, but its interaction with nutrient deficiencies is often overlooked.

Purpose of the Study:

  • To review the bidirectional relationship between micronutrient deficiency and gut dysbiosis in MASLD.
  • To elucidate how gut dysbiosis impacts micronutrient bioavailability and perpetuates liver disease.
  • To highlight the need for integrated therapeutic strategies for MASLD management.

Main Methods:

  • Literature review focusing on the interplay between micronutrients, gut microbiota, and MASLD.
  • Analysis of emerging evidence on the mechanisms linking nutrient depletion, dysbiosis, and hepatic dysfunction.
  • Synthesis of findings to inform potential therapeutic interventions.

Main Results:

  • Micronutrient deficiencies independently contribute to MASLD pathogenesis.
  • Gut dysbiosis exacerbates MASLD and impairs micronutrient absorption, creating a vicious cycle.
  • The relationship between micronutrient status and gut microbial composition is complex and bidirectional.

Conclusions:

  • Effective MASLD management requires addressing both nutritional deficiencies and gut microbial imbalances.
  • Prebiotic and probiotic interventions show potential for restoring microbial balance and improving nutrient absorption.
  • Personalized therapies combining microbiota modulation and micronutrient repletion may offer a promising future for MASLD treatment.

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.7K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
650
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
684
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204